Page last updated: 2024-09-03

ezogabine and Aura

ezogabine has been researched along with Aura in 49 studies

Research

Studies (49)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (8.16)	18.2507
2000's	11 (22.45)	29.6817
2010's	28 (57.14)	24.3611
2020's	6 (12.24)	2.80

Authors

Authors	Studies
Amato, GS; Burns, JF; Eargle, CW; Fritch, PC; Harrison, W; Jones, L; McNaughton-Smith, G; Roeloffs, R; Wickenden, AD	1
Du, X; Fu, Y; Jia, Q; Mi, Y; Qi, J; Wang, K; Wu, Y; Xu, W; Zhang, D; Zhang, F; Zhang, H	1
Arora, G; Baker, K; Boscoe, BP; Butler, CR; Chenard, L; Claffey, MM; Clark, AJ; Davoren, JE; DeNinno, SL; Drozda, SE; Duplantier, AJ; Lowe, JA; Mather, RJ; Moine, L; Reese, MR; Rogers, BN; Rong, H; Rong, S; Schuyten, K; Serpa, KA; Snow, SL; Stolyar, P; Tse, K; Weber, ML; Whisman, TL; Wright, AS; Zhang, L	1
Lu, D; Ouyang, P; Yang, S	2
Bakshi, T; Bhamidipati, R; Brady, P; Cato, M; Chapman, M; Chaudhary, KW; Donovan, B; Dougherty, RW; Downie, D; Fu, T; Higgins, GA; Holenz, J; Kuppusamy, BM; Lin, H; Lluel, P; Madhyastha, N; Matsuoka, Y; Mohd, Z; Morrow, D; Pasikanti, K; Rajagopal, S; Rouget, C; Samanta, SK; Seefeld, MA; Zhen, W	1
Bialer, M; Johannessen, SI; Koepp, MJ; Levy, RH; Perucca, E; Perucca, P; Tomson, T; White, HS	1
Bleakley, LE; McKenzie, CE; Reid, CA	1
Kelly, M; Knight, D; Mahida, S; Olson, HE; Poduri, A	1
Dong, H; Feng, S; Lin, L; Liu, Y; Shi, G; Tian, Y; Zhao, F	1
Allison, WT; Kanyo, R; Kurata, HT; Li, J; Locskai, LF; Wang, CK	1
Ambrosino, P; Binda, A; Canafoglia, L; Castellotti, B; DiFrancesco, JC; Freri, E; Gellera, C; Granata, T; Labalme, A; Lesca, G; Messina, G; Mosca, I; Murano, C; Ragona, F; Rivolta, I; Solazzi, R; Soldovieri, MV; Taglialatela, M; Vannicola, C	1
Ambrosino, P; Manocchio, L; Miceli, F; Mosca, I; Soldovieri, MV; Taglialatela, M	1
Gautier, NM; Glasscock, E; Mishra, V; Vanhoof-Villalba, SL	1
Gao, Z; Gu, M; Li, M; Nan, FJ; Yu, H; Zhou, P	1
Ilickovic, I; Jankovic, S	1
Hatch, RJ; Petrou, S; Reid, CA	1
Bell, GS; Chinnasami, S; Duncan, JS; Novy, J; Sander, JW; Wehner, T	1
Bocchicchio, M; Huber, B	1
Duignan, KM; Edwards, S; Furuya, T; Kalappa, BI; Soh, H; Tzingounis, AV; Tzounopoulos, T	1
Lopez-Garcia, JA; Rivera-Arconada, I; Vicente-Baz, J	1
Lerche, H; Maljevic, S; Seebohm, G; Wuttke, TV	1
Deeks, ED	1
Szupera, Z	1
Gunthorpe, MJ; Large, CH; Sankar, R	1
Crean, CS; Gunthorpe, MJ; Large, CH; Nehlig, A; Sankar, R; Sokal, DM; Vanlandingham, KE; White, HS	1
Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG	1
Berry, DJ; Patsalos, PN	1
Forcelli, PA; Gale, K; Kondratyev, A; Lakhkar, A; Soper, C	1
Mula, M	1
Lerche, H; Nies, AT; Orhan, G; Schwab, M; Wuttke, TV	1
Hopkins, CR	1
Kumar, M; Kumar, R; Verma, A	1
Brandt, C; Ebert, U; Löscher, W	1
Dworetzky, SI; Wua, YJ	1
Blackburn-Munro, G; Blackburn-Munro, RE; Dalby-Brown, W; Mikkelsen, JD; Mirza, NR	1
Green, AC; Harrison, PK; Sheridan, RD; Tattersall, JE	1
Nohria, V; Porter, RJ; Rundfeldt, C	1
Kwon, YS; Mazarati, A; Sankar, R; Shin, D; Wu, J	1
Adams-Curtis, LE; Cheong, JH; Dailey, JW; Jobe, PC; Ko, KH	1
Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E	1
Armand, V; Heinemann, U; Rundfeldt, C	2
Rundfeldt, C	1
Dost, R; Rundfeldt, C	1
Lawson, K	1
Cooper, EC	1

Reviews

15 review(s) available for ezogabine and Aura

Article	Year
Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites. Current medicinal chemistry, 2018, Volume: 25, Issue:23 Topics: Animals; Carbamates; Epilepsy; Humans; Indoles; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Membrane Transport Modulators; Neurons; Phenylenediamines; Potassium Channel Blockers; Pyridines	2018
KV7 channelopathies. Pflugers Archiv : European journal of physiology, 2010, Volume: 460, Issue:2 Topics: Animals; Carbamates; Channelopathies; Epilepsy; Humans; KCNQ Potassium Channels; Long QT Syndrome; Mutation; Phenylenediamines	2010
Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. CNS drugs, 2011, Oct-01, Volume: 25, Issue:10 Topics: Anticonvulsants; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epilepsy; Humans; Phenylenediamines; Randomized Controlled Trials as Topic; Seizures	2011
[New antiepileptic drugs, and therapeutic considerations]. Ideggyogyaszati szemle, 2011, Sep-30, Volume: 64, Issue:9-10 Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Epilepsy; Humans; Lacosamide; Phenylenediamines	2011
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia, 2012, Volume: 53, Issue:3 Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Rats; Treatment Outcome	2012
Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:5 Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Drug Interactions; Epilepsy; Humans; Lacosamide; Phenylenediamines	2012
Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Expert review of neurotherapeutics, 2012, Volume: 12, Issue:6 Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Epilepsy; Forecasting; Humans; Lacosamide; Phenylenediamines	2012
Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:12 Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Membrane Transport Modulators; Phenylenediamines	2012
ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine). ACS chemical neuroscience, 2012, Aug-15, Volume: 3, Issue:8 Topics: Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Potassium Channels; Randomized Controlled Trials as Topic; Seizures; United States; United States Food and Drug Administration	2012
Ezogabine: development and role in the management of epileptic seizures. Mini reviews in medicinal chemistry, 2013, Apr-01, Volume: 13, Issue:5 Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Epilepsy; Half-Life; Humans; Phenylenediamines; Potassium Channels	2013
Recent developments on KCNQ potassium channel openers. Current medicinal chemistry, 2005, Volume: 12, Issue:4 Topics: Acrylamides; Aminopyridines; Benzamides; Carbamates; Epilepsy; Humans; Indoles; Ion Channel Gating; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Migraine Disorders; Oxindoles; Pain; Phenylenediamines; Potassium Channels, Voltage-Gated	2005
Retigabine: chemical synthesis to clinical application. CNS drug reviews, 2005,Spring, Volume: 11, Issue:1 Topics: Animals; Anticonvulsants; Anxiety; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Humans; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Neurons; Pain; Phenylenediamines; Potassium Channels, Voltage-Gated; Time Factors	2005
Retigabine. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007, Volume: 4, Issue:1 Topics: Animals; Anticonvulsants; Brain; Carbamates; Clinical Trials as Topic; Epilepsy; Humans; Phenylenediamines	2007
Is there a role for potassium channel openers in neuronal ion channel disorders? Expert opinion on investigational drugs, 2000, Volume: 9, Issue:10 Topics: Aminopyridines; Animals; Anticonvulsants; Antihypertensive Agents; Ataxia; Carbamates; Diazoxide; Epilepsy; Humans; Ion Channels; Isaacs Syndrome; Membrane Potentials; Mice; Mice, Neurologic Mutants; Mutation; Nervous System Diseases; Neuroprotective Agents; Parkinson Disease; Phenylenediamines; Potassium Channels	2000
Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs. Epilepsia, 2001, Volume: 42 Suppl 5 Topics: Animals; Anticonvulsants; Carbamates; Clinical Trials as Topic; Drug Design; Epilepsy; Epilepsy, Benign Neonatal; Humans; Mutation; Neurons; Phenylenediamines; Potassium Channels; Potassium Channels, Voltage-Gated; Receptors, Muscarinic; Synaptic Transmission	2001

Other Studies

34 other study(ies) available for ezogabine and Aura

Article	Year
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain. Journal of medicinal chemistry, 2010, Jan-28, Volume: 53, Issue:2 Topics: Adamantane; Animals; Azides; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Mice; Neuralgia; Structure-Activity Relationship	2010
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators. European journal of medicinal chemistry, 2011, Volume: 46, Issue:3 Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Cricetinae; Cricetulus; Drug Design; Epilepsy; Humans; KCNQ Potassium Channels; Patch-Clamp Techniques; Pyrazoles; Pyrimidines; Rubidium; Structure-Activity Relationship	2011
Discovery of a novel Kv7 channel opener as a treatment for epilepsy. Bioorganic & medicinal chemistry letters, 2015, Nov-01, Volume: 25, Issue:21 Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Drug Discovery; Electroshock; Epilepsy; Humans; Ion Channel Gating; KCNQ2 Potassium Channel; Microsomes; Molecular Structure; Piperidines; Pyrimidines; Rats; Structure-Activity Relationship	2015
Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents. Bioorganic & medicinal chemistry letters, 2018, 06-01, Volume: 28, Issue:10 Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Humans; KCNQ Potassium Channels; Molecular Structure; Piperidines; Structure-Activity Relationship	2018
Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy. Bioorganic & medicinal chemistry letters, 2018, 09-15, Volume: 28, Issue:17 Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Exercise Test; KCNQ Potassium Channels; Mice; Molecular Structure; Phenylbutyrates; Potassium Channel Blockers; Rats; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution	2018
Novel K Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24 Topics: Animals; Anticonvulsants; Epilepsy; Humans; KCNQ Potassium Channels; Mice; Muscle Contraction; Muscle, Smooth; Protein Isoforms; Seizures; Urinary Bladder	2018
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development. Epilepsia, 2022, Volume: 63, Issue:11 Topics: Anticonvulsants; Child; Drugs, Investigational; Epilepsy; Humans; Research Report	2022
Efficacy of antiseizure medication in a mouse model of HCN1 developmental and epileptic encephalopathy. Epilepsia, 2023, Volume: 64, Issue:1 Topics: Animals; Anticonvulsants; Epilepsy; Epilepsy, Generalized; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Lamotrigine; Mice; Potassium Channels; Seizures; Valproic Acid	2023
Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy. Epilepsia, 2023, Volume: 64, Issue:7 Topics: Child, Preschool; Epilepsy; Epilepsy, Generalized; Humans; Infant; KCNQ2 Potassium Channel; Mutation; Retrospective Studies; Seizures	2023
An Electrochemophysiological Microarray for Real-Time Monitoring and Quantification of Multiple Ions in the Brain of a Freely Moving Rat. Angewandte Chemie (International ed. in English), 2020, 06-22, Volume: 59, Issue:26 Topics: Animals; Anticonvulsants; Brain; Calcium; Carbamates; Diamines; Electrochemical Techniques; Epilepsy; Hydrogen-Ion Concentration; Ionophores; Limit of Detection; Male; Microelectrodes; Monitoring, Physiologic; Phenylenediamines; Potassium; Rats, Wistar; Sodium; Zonisamide	2020
Functional and behavioral signatures of Kv7 activator drug subtypes. Epilepsia, 2020, Volume: 61, Issue:8 Topics: Anilides; Animals; Animals, Genetically Modified; Anticonvulsants; Bridged Bicyclo Compounds; Calcium; Carbamates; Disease Models, Animal; Drug Resistance; Epilepsy; In Vitro Techniques; KCNQ Potassium Channels; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Luminescent Proteins; Membrane Potentials; Mutation; Neurons; Optical Imaging; Patch-Clamp Techniques; Phenylenediamines; Seizures; Zebrafish	2020
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy. Pharmacological research, 2020, Volume: 160 Topics: Age of Onset; Animals; Anticonvulsants; Carbamates; Cells, Cultured; Child; CHO Cells; Cricetinae; Cricetulus; Electroencephalography; Epilepsy; Female; Gabapentin; Humans; KCNQ2 Potassium Channel; Mutation; Phenylenediamines; Precision Medicine; Rats; Treatment Outcome	2020
Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy. Epilepsia, 2018, Volume: 59, Issue:2 Topics: Animals; Anticonvulsants; Atrioventricular Block; Behavior, Animal; Bradycardia; Carbamates; Channelopathies; Death, Sudden; Disease Models, Animal; Drug Resistance; Drug Resistant Epilepsy; Electroencephalography; Epilepsy; Gene Expression Profiling; Heart Rate; KCNQ Potassium Channels; KCNQ1 Potassium Channel; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Kv1.1 Potassium Channel; Mice; Nerve Tissue Proteins; Pharmacogenetics; Pharmacogenomic Testing; Phenylenediamines; RNA, Messenger; Transcriptome	2018
Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels. Proceedings of the National Academy of Sciences of the United States of America, 2013, May-21, Volume: 110, Issue:21 Topics: Animals; Anticonvulsants; Carbamates; CHO Cells; Cricetinae; Cricetulus; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Keratolytic Agents; Mice; Mutation; Nerve Tissue Proteins; Neurons; Organometallic Compounds; Phenylenediamines; Phosphatidylinositol 4,5-Diphosphate; Pyridines; Signal Transduction	2013
The preclinical discovery and development of ezogabine for the treatment of epilepsy. Expert opinion on drug discovery, 2013, Volume: 8, Issue:11 Topics: Animals; Anticonvulsants; Carbamates; Drug Discovery; Epilepsy; Humans; Phenylenediamines; Product Surveillance, Postmarketing	2013
Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy. Epilepsia, 2014, Volume: 55, Issue:4 Topics: Action Potentials; Animals; Anticonvulsants; CA1 Region, Hippocampal; Carbamates; Carbamazepine; Disease Models, Animal; Epilepsy; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Net; Organ Culture Techniques; Phenylenediamines; Up-Regulation; Voltage-Gated Sodium Channel beta-1 Subunit	2014
Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure, 2014, Volume: 23, Issue:10 Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Drug Resistance; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Phenylenediamines; Piracetam; Time; Treatment Outcome; Young Adult	2014
A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy. Epilepsy & behavior : E&B, 2015, Volume: 44 Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Cohort Studies; Epilepsy; Female; Humans; Intellectual Disability; Male; Middle Aged; Phenylenediamines; Retrospective Studies; Treatment Outcome; Young Adult	2015
Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Jun-10, Volume: 35, Issue:23 Topics: Animals; Animals, Newborn; Anticonvulsants; Carbamates; Disease Models, Animal; Epilepsy; Evoked Potentials, Auditory, Brain Stem; Female; HEK293 Cells; Homeodomain Proteins; Humans; In Vitro Techniques; KCNQ Potassium Channels; KCNQ2 Potassium Channel; Male; Membrane Potentials; Mice; Mice, Inbred ICR; Mice, Knockout; Mutation; Phenylenediamines; Rats; Rats, Sprague-Dawley; Tinnitus; Transcription Factors	2015
Targeting Kv7 channels in pain pathways. Oncotarget, 2017, Feb-21, Volume: 8, Issue:8 Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channels; Long QT Syndrome; Mutation; Neurons; Pain; Pain Management; Phenylenediamines; Protein Conformation	2017
Deal watch: GSK acquires rights to Valeant's anti-epileptic drug. Nature reviews. Drug discovery, 2008, Volume: 7, Issue:11 Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Commerce; Drug Industry; Epilepsy; Legislation, Drug; Phenylenediamines	2008
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia, 2012, Volume: 53, Issue:3 Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Drug Synergism; Epilepsy; Humans; KCNQ Potassium Channels; Neurons; Phenylenediamines; Treatment Outcome	2012
[Neurology]. Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323 Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid	2012
Retigabine: fewer drug interactions. Prescrire international, 2012, Volume: 21, Issue:125 Topics: Anticonvulsants; Carbamates; Drug Interactions; Drug Therapy, Combination; Epilepsy; Humans; Phenylenediamines; Randomized Controlled Trials as Topic	2012
Anticonvulsant effect of retigabine during postnatal development in rats. Epilepsy research, 2012, Volume: 101, Issue:1-2 Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Convulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Injections, Subcutaneous; Kindling, Neurologic; Pentylenetetrazole; Phenylenediamines; Pregnancy; Rats; Rats, Sprague-Dawley; Seizures	2012
Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia, 2002, Volume: 43 Suppl 5 Topics: Animals; Anticonvulsants; Apoptosis; Biomarkers; Carbamates; Caspase Inhibitors; Dizocilpine Maleate; Enzyme Inhibitors; Epilepsy; Female; Hippocampus; Limbic System; Neuroprotective Agents; Phenylenediamines; Rats; Rats, Wistar; Sclerosis; Status Epilepticus; Time Factors	2002
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus. European journal of pharmacology, 2005, Aug-22, Volume: 518, Issue:2-3 Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Epilepsy; Felbamate; Fructose; Gabapentin; gamma-Aminobutyric Acid; Guinea Pigs; Hippocampus; In Vitro Techniques; Levetiracetam; Male; Phenylcarbamates; Phenylenediamines; Piracetam; Propylene Glycols; Soman; Topiramate	2005
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia, 2008, Volume: 49, Issue:10 Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Carbamates; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Epilepsy; Hippocampus; Kindling, Neurologic; Male; Motor Activity; Phenylenediamines; Rats; Rats, Wistar; Time Factors	2008
Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neuroscience letters, 1995, Aug-04, Volume: 195, Issue:2 Topics: Animals; Anticonvulsants; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Female; Male; Phenylenediamines; Rats; Rats, Inbred Strains	1995
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference. Epilepsy research, 1996, Volume: 25, Issue:3 Topics: Acetamides; Animals; Anticonvulsants; Azetidines; Carbamates; Drug Evaluation, Preclinical; Drugs, Investigational; Epilepsy; Humans; Israel; Levetiracetam; Nipecotic Acids; Phenylenediamines; Piracetam; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Thiazoles; Tiagabine; Triazoles	1996
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn-Schmiedeberg's archives of pharmacology, 1999, Volume: 359, Issue:1 Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Carbamates; Convulsants; Electrophysiology; Entorhinal Cortex; Epilepsy; Excitatory Amino Acid Antagonists; In Vitro Techniques; Phenylenediamines; Rats; Rats, Wistar; Seizures	1999
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy research, 1999, Volume: 35, Issue:2 Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Electrophysiology; Epilepsy; Nerve Growth Factor; PC12 Cells; Phenylenediamines; Potassium Channels; Rats	1999
The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation. Epilepsy research, 2000, Volume: 38, Issue:1 Topics: Animals; Anticonvulsants; Calcium; Carbamates; Electrophysiology; Epilepsy; gamma-Aminobutyric Acid; Hippocampus; In Vitro Techniques; Magnesium Deficiency; Male; Phenylenediamines; Potassium Channels; Rats; Rats, Wistar	2000
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia, 2000, Volume: 41, Issue:1 Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Electroencephalography; Entorhinal Cortex; Epilepsy; Hippocampus; Magnesium Deficiency; Phenylenediamines; Rats; Rats, Wistar	2000